The novel GLP‐1/GIP analogue DA5‐CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD

Brain and Behavior - Tập 10 Số 3 - 2020
Li Cheng1, Weizhen Liu1, Xiaohui Li1, Zijuan Zhang1, Huaxin Qi1, Shijin Liu1, Ningning Yan1, Ying Xing1, Christian Hölscher2, Zhiju Wang1
1Department of Physiology and Neurobiology, School of Medicine, Zhengzhou University, Zhengzhou, Henan, PR China
2Research and Experimental Center, Henan University of Chinese Medicine, Zhengzhou, Henan, PR China

Tóm tắt

AbstractIntroductionAlzheimer's disease (AD) is the most common progressive neurodegenerative disease for which there is no cure. Recent studies have shown a close link between type 2 diabetes and AD, which suggested that drugs for type 2 diabetes may be effective for AD. GLP‐1 and GIP are incretin hormones that can ameliorate diabetes.MethodsIn the present study, we tested the novel dual GLP‐1/GIP receptor agonist DA5‐CH in the icv. streptozotocin (STZ)‐induced insulin desensitization model of AD in rats to explore the protective effects of DA5‐CH.ResultsThe results show that DA5‐CH could reverse the STZ‐induced working memory impairments in a Y‐maze tests, and spatial memory impairments in the water maze task, and decrease the levels of phosphorylated tauS396 protein in the hippocampus. In EEG recordings, STZ treatment diminished the power of the theta band frequency. DA5‐CH was able to increase the energy of theta band activity in the hippocampal CA1 region. The drug also increased the expression of synapse‐related proteins in the hippocampus. After DA5‐CH treatment, mitochondrial stress was alleviated as shown by the improved ratio of Bax/Bcl‐2 in the hippocampus. Growth factor signaling was also normalized as shown by the increased level of the transcription factor P‐CREBS133. In addition, we were able to show that DA5‐CH can cross the blood–brain barrier at an increased rate compared with other dual GLP‐1/GIP or single GLP‐1 receptor agonists.ConclusionTherefore, our results demonstrate that DA5‐CH has neuroprotective effects in the STZ‐induced animal model and that DA5‐CH has potential to treat neurodegenerative disorders such as AD.

Từ khóa


Tài liệu tham khảo

10.1073/pnas.121119298

10.1186/1744-8069-2-15

10.1016/0092-8674(94)90400-6

10.1016/S0896-6273(02)00586-X

10.1016/j.bbr.2016.10.033

10.1016/j.bbrc.2017.11.114

10.1097/WNR.0000000000000548

10.1016/j.ejphar.2018.03.024

10.1016/0166-4328(95)00214-6

10.1093/hmg/ddq160

10.4331/wjbc.v1.i5.81

10.1007/s12031-011-9583-6

10.1016/j.neuroscience.2012.10.045

10.3233/JAD-121888

10.1016/j.neuropharm.2018.02.012

10.1126/scitranslmed.3007218

10.1016/j.brainresrev.2004.07.018

10.1111/bpa.12116

10.1515/revneuro-2013-0034

10.1016/S0046-8177(86)80080-6

10.1097/WNR.0000000000000490

10.1016/j.brainres.2015.12.052

10.1530/JOE-13-0221

10.1042/BST20140016

10.1016/j.neuropharm.2018.01.040

10.1186/1471-2202-13-33

10.1128/MCB.02353-05

10.1016/S0896-6273(00)80120-8

10.1016/j.brainres.2009.04.010

10.1016/j.neuropharm.2017.02.013

10.1111/j.1582-4934.2001.tb00134.x

10.1016/j.brainres.2015.09.035

10.3233/JAD-2010-100879

10.1038/sj.ijo.0802206

10.1385/JMN:18:1-2:07

10.1074/jbc.M500540200

10.1016/0896-6273(89)90077-9

10.1007/978-3-211-98811-4_32

10.3233/JAD-2006-9102

10.1016/j.brainresrev.2007.09.001

10.1016/j.ejphar.2011.11.005

10.3233/JAD-2010-1314

10.1016/j.neuropharm.2015.10.002

10.1016/j.ejphar.2016.11.050

10.1111/j.1471-4159.2007.04942.x

Liu Z.‐B., 2011, Effect of "Xiusanzhen"on expression of hippocampal Bcl‐2 and Bax proteins in Alzheimer disease rats., Zhen ci yan jiu=Acupuncture Research, 36, 7

10.1212/01.WNL.0000140292.04932.87

10.1152/ajpendo.00665.2010

10.3390/ijms15045596

10.1016/j.neuropharm.2013.08.005

10.1016/j.neuropharm.2014.07.015

10.1523/JNEUROSCI.0529-11.2011

10.1016/j.neurobiolaging.2008.04.002

10.1007/s11064-011-0475-5

10.1212/WNL.53.9.1937

Paramanik V., 2013, Role of CREB signaling in aging brain, Archives Italiennes De Biologie, 151, 33

10.3233/JAD-2002-4605

10.1007/s00702-010-0523-3

10.1038/s41598-018-19154-y

10.1523/JNEUROSCI.1450-06.2006

10.1523/JNEUROSCI.5291-04.2005

10.1345/aph.140065

10.1002/j.1460-2075.1986.tb04243.x

Salkovic‐Petrisic M., 2007, Central insulin resistance as a trigger for sporadic Alzheimer‐like pathology: An experimental approach, Journal of Neural Transmission‐Supplement, 72, 217

10.1111/jnc.12469

10.1016/j.bbr.2017.03.032

10.3233/JAD-2005-7107

10.1016/j.neuron.2008.10.014

10.1172/JCI59903

10.1016/j.expneurol.2016.11.005

10.1002/ana.410300410

Thind K., 2007, Pathological correlates of cognitive decline in Alzheimer's disease, Panminerva Medica, 49, 191

10.1111/j.1460-9568.2006.05226.x

10.1126/science.663646

10.1152/jn.2000.83.4.2138

10.1111/acel.12449

Zhang Y., 2018, Effect of intraperitoneal or intracerebroventricular injection of streptozotocin on learning and memory in mice, Experimental and Therapeutic Medicine, 16, 2375

Thông tin
Thông tin xuất bản

Brain and Behavior

Tập 10 Số 3

Thông tin tác giả